Ian Mortimer, Xenon Pharmaceuticals CEO
Despite failing its PhII test, Xenon sees future for major depression drug
Xenon Pharmaceuticals’ major depressive disorder drug candidate didn’t reach statistical significance versus placebo in the primary endpoint of a mid-stage trial, but the Canadian biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.